Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan

Japanese Journal of Infectious Diseases

Volumn 59, Issue 4, 2006, Pages 222-228

  Hung, Chien Ching ^a   Hsiao, Chin Fu ^b,c   Chen, Mao Yuan ^a   Hsieh, Szu Min ^a   Chang, Sui Yuan ^c   Sheng, Wang Huei ^a   Sun, Hsin Yun ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERINFECTION; SURVIVAL; TAIWAN; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; TAIWAN;

EID: 33748120952     PISSN: 13446304     EISSN: 13446304     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J. and Holmberg, S. D. (1998): Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med., 338, 853-860.
2. Lee, L. M., Karon, J. M., Selik, R., Neal, J. J. and Fleming, P. L. (2001): Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA, 285, 1308-1315.
3. Murphy, E. L., Collier, A. C., Kalish, L. A., Assmann, S. F., Para, M. F., Flanigan, T. P., Kumar, P. N., Mintz, L., Wallach, F. R. and Nemo, G. J. (2001): Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med, 135, 17-26.
4. Dore, G. J., Li, Y., McDonald, A., Ree, H. and Kaldor, J. M. (2002): Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J. Acquired Immun. Defic. Syndr., 29, 388-395.
5. Egger, M., May, M., Chene, G., Phillips, A. N., Ledergerber, B., Dabis, F., Costagliola, D., D'Arminio Monforte, A., de Wolf, F., Reiss, P., Lundgren, J. D., Justice, A. C., Staszewski, S., Leport, C., Hogg, R. S., Sabin, C. A., Gill, M. J., Salzberger, B. and Sterne, J. A. (2002): Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet, 360, 119-129.
6. Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss, P., d'Arminio Monforte, A., Knysz, B., Dietrich, M., Phillips, A. N. and Lundgren, J. D. (2003): Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet, 362, 22-29.
7. Porter, K., Babiker, A., Bhaskaran, K., Darbyshire, J., Pezzotti, P., Porter, K. and Walker, A. S. (2003): Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet, 362, 1267-1274.
8. Grabar, S., Le Moing, V., Goujard, C., Leport, C., Kazatchkine, M. D., Costagliola, D. and Weiss, L. (2000): Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med., 133, 401-410.
9. Hogg, R. S., Yip, B., Chan, K. J., Wood, E., Craib, K. J., O'Shaughnessy, M. V. and Montaner, J. S. (2001): Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA, 286, 2568-2577.
10. Palella, F. J., Jr., Deloria-Knoll, M., Chmiel, J. S., Moorman, A. C., Wood, K. C., Greenberg, A. E. and Holmberg, S. D. (2003): Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann. Intern. Med., 138, 620-626.
11. 9 cells/L. Ann. Intern. Med., 139, 810-816.
12. Chene, G., Sterne, J. A., May, M., Costagliola, D., Ledergerber, B., Phillips, A. N., Dabis, F., Lundgren, J., D'Arminio Monforte, A., de Wolf, F., Hogg, R., Reiss, P., Justice, A., Leport, C., Staszewski, S., Gill, J., Fatkenheuer, G. and Egger, M. E. (2003): Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet, 362, 679-686.
13. Sterling, T. R., Chaisson, R. E., Keruly, J. and Moore, R. D. (2003): Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J. Infect. Dis., 188, 1659-1665.
14. Conti, S., Masocco, M., Pezzotti, P., Toccaceli, V., Vichi, M., Crialesi, R., Frova, L. and Rezza, G. (2002): Excess mortality from liver disease and other non-AIDS-related diseases among HIV-infected individuals in Italy. J. Acquired Immun. Defic. Syndr., 29, 105-107.
15. Louie, J. K., Hsu, L. C., Osmond, D. H., Katz, M. H. and Schwarcz, S. K. (2002): Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. J. Infect. Dis., 186, 1023-1027.
16. Mocroft, A., Brettle, R., Kirk, O., Blaxhult, A., Parkin, J. M., Antunes, F., Francioli, P., D'Arminio Monforte, A., Fox, Z. and Lundgren, J. D. (2002): Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS, 16, 1663-1671.
17. Jain, M. K., Skiest, D. J., Cloud, J. W., Jain, C. L., Burns, D. and Berggren, R. E. (2003): Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin. Infect. Dis., 36, 1030-1038.
18. Lewden, C., Salmon, D., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T. and Chene, G. (2005): Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int. J. Epidemiol., 34, 121-130.
19. Centers for Disease Control and Prevention (1992): 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Wkly. Rep., RR41, 1-19.
20. Hung, C. C., Chen, M. Y., Hsieh, S. M., Sheng, W. H. and Chang, S. C. (2000): Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study. J. Acquired Immun. Defic. Syndr., 24, 378-385.
21. Wong, K. H., Chan, K. C. and Lee, S. S. (2004): Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy. Clin. Infect. Dis., 39, 853-860.
22. Center for Disease Control, Taiwan. Statistics of HIV infection and AIDS in Taiwan. Online at . Accessed 31 January 2006.
23. Chen, Y. M., Lee, C. M., Lin, R. Y. and Chang, H. J. (1998): Molecular epidemiology and trends of HIV-1 subtypes in Taiwan. J. Acquired Immun. Defic. Syndr. Hum. Retrovirol., 19, 393-402.
24. Lee, C. N., Wang, W. K., Fan, W. S., Twu, S. J., Chen, S. C., Sheng, M. C. and Chen, M. Y. (2000): Determination of human immunodeficiency virus type 1 subtypes in Taiwan by vpu gene analysis. J. Clin. Microbiol., 38, 2468-2474.
25. Kaplan, J. E., Masur, H. and Holmes, K. K. (2002): Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Morbid. Mortal. Wkly. Rep., RR51, 1-52.
26. U.S. Department of Health and Human Services (2006): Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. The Panel on Clinical Practice for Treatment of HIV Infection. Online at .
27. Zhou, J., Kumarasamy, N., Ditangco, R., Kamarulzaman, A., Lee, C. K., Li, P. C., Paton, N. I., Phanuphak, P., Pujari, S., Vibhagool, A., Wong, W. W., Zhang, F., Chuah, J., Frost, K. R., Cooper, D. A. and Law, M. G. (2005): The TREAT Asia HIV Observational Database: baseline and retrospective data. J. Acquired Immun. Defic. Syndr., 38, 174-179.
28. Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P. and Rinaldo, C. R., Jr. (1997): Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126, 946-954.
29. Wood, E., Hogg, R. S., Yip, B., Quercia, R., Harrigan, P. R., O'Shaughnessy, M. V. and Montaner, J. S. (2003): Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J. Infect. Dis., 188, 1421-1425.
30. Phillips, A. N., Staszewski, S., Weber, R., Kirk, O., Francioli, P., Miller, V., Vernazza, P., Lundgren, J. D. and Ledergerber, B. (2001): HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA, 286, 2560-2567.
31. Anderson, K. B., Guest, J. L. and Rimland, D. (2004): Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin. Infect. Dis., 39, 1507-1513.
32. Thio, C. L., Seaberg, E. C., Skolasky, R., Jr., Phair, J., Visscher, B., Munoz, A. and Thomas, D. L. (2002): HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet, 360, 1921-1926.
33. Konopnicki, D., Mocroft, A., de Wit, S., Antunes, F., Ledergerber, B., Katlama, C., Zilmer, K., Vella, S., Kirk, O. and Lundgren, J. D. (2005): Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS, 19, 593-601.
34. Salmon-Ceron, D., Lewden, C., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T. and Chene, G. (2005): Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol., 42, 799-805.
35. Qurishi, N., Kreuzberg, C., Luchters, G., Effenberger, W., Kupfer, B., Sauerbruch, T., Rockstroh, J. K. and Spengler, U. (2003): Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet, 362, 1708-1713.
36. Hung, C. C., Chen, M. Y., Hsiao, C. F., Hsieh, S. M., Sheng, W. H. and Chang, S. C. (2003): Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS, 17, 2615-2622.
37. Shieh, B., Liau, Y. E., Yan, Y. P., Sun, H. S., Chen, M. Y., Liu, Y. C., Ko, N. Y. and Li, C. (1999): Alleles that may influence HIV-1 pathogenesis in Chinese subjects. AIDS, 13, 421-424.